Infectious Diseases Research

Below are current clinical trials.

259 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study to Better Understand the Immune Response to the Flu Vaccine (MF59) and the High Dose Flu Vaccine (HDFlu) in People 65 Years of Age and Older

   Rochester, Minn.

   The purpose of this research study is to better understand the immune response to the Adjuvanted Subunit flu vaccine (MF59) and the High Dose flu vaccine (HDFlu) in people 65 years of age and older.

2. A Study to Create a Standard Set of Outcomes in from Which to Gauge Outcomes in Patients with Prosthetic Joint Infections

   Rochester, Minn.

   The aim of this study is to create a standard set of outcome parameters which can be adopted nationwide from which to gauge outcomes in Prosthetic Joint Infections (PJI).

3. Comparison of Respiratory Pathogen Detection in Upper Versus Lower Respiratory Tract Samples using the Biofire Filmarray Respiratory Panel

   Rochester, Minn.

   The purpose of this study is to compare the performance of the FilmArray Respiratory Panel in nasopharyngeal (NP) swabs and bronchoalveolar lavage (BAL) fluid collected from immunocompromised hosts (ICH).

4. Lymphoid Tissue Examination

   Rochester, Minn.

   The purpose of this study is to study HIV infected individuals or others who have had another infection or inflammatory condition that may affect the content or structure of lymph nodes or may have none of these conditions and the sample will be used as a normal control.

5. A Study to Evaluate the Relationship Between Vaginal and Lower Urinary Tract Microbiomes and Infection After A Hysterectomy

   Rochester, Minn.

   The purpose of this study is to learn more about the microbes (bacteria) that live in the vagina and the bladder. The investigators are doing this research study to understand the relationship between microbes (the microbiome) and the occurrence of urinary tract infection following surgical removal of the uterus and pelvic organ prolapse repair.

6. A Study to Evaluate the Outcome of Patients with Prosthetic Joint Infection

   Rochester, Minn.

   The purpose of this study is to assess the outcome of prosthetic joint infection (PJI) treated with various therapeutic regimens using a prospective cohort study.

7. Fecal Microbiota Transplantation For C. Difficile Infection In Solid Organ Transplant Recipients

   Rochester, Minn.

   The purpose of this trial is to examine the effect of Fecal Microbiota Transplantation (FMT) compared with Vancomycin for cure of recurrent C. diff infection (CDI) in solid organ transplant (SOT) recipients in a randomized, controlled clinical trial.

8. A Study To Evaluate The Efficacy And Safety Of A Vaccine, ASP0113, In Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving An Organ From A CMV-Seropositive Donor

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also evaluate the safety of ASP0113 in this patient population.

9. SER-262 Versus Placebo In Adults With Primary Clostridium Difficile Infection To Prevent Recurrence

   Rochester, Minn.

   The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of investigational drug versus placebo in adults with primary (first episode) Clostridium difficile infection (CDI).

10. A Randomized, Double-Blind, Multicenter, Phase 3 Study Of The Efficacy, Safety, And Tolerability Of Brincidofovir Versus Valganciclovir For The Prevention Of Cytomegalovirus Disease In CMV Seronegative Kidney Allograft Recipients

    Rochester, Minn.

    To compare the efficacy of brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of cytomegalovirus (CMV) disease in kidney transplant allograft recipients who are CMV seronegative pretransplant and received a kidney from a CMV seropositive donor.